Phenominer Database Results (73 results)

 

How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Clinical Measurement Notes Record ID Study ID
SS.ZUC-Leprfa-/-/Slc heart ventricle septal wall thickness atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle wall thickness male 91 days 13 0.2 cm 0.0 0.01 echocardiography 0.0 0 101994 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricle end-diastolic diameter atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle end-diastolic diameter male 91 days 13 8.56 mm 0.08 0.29 echocardiography 0.0 0 101996 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricle posterior wall thickness bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle posterior wall thickness female 91 days 8 2.06 mm 0.04 0.11 echocardiography 0.0 ovariectomy 42 days 101713 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricle posterior wall thickness bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle posterior wall thickness female 91 days 7 2.16 mm 0.06 0.16 echocardiography 0.0 ovariectomy 42 days 101714 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricle fractional shortening bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle end-diastolic diameter female 91 days 8 47.7 % 1.9 5.37 echocardiography 0.0 ovariectomy 42 days 101721 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricle relative wall thickness bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle wall thickness female 91 days 7 61.0 % 2.0 5.29 echocardiography 0.0 ovariectomy 42 days 101730 2622
SS.ZUC-Leprfa-/-/Slc E wave deceleration time bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait female 91 days 8 56.9 ms 1.8 5.09 echocardiography 0.0 ovariectomy 42 days 101733 2622
SS.ZUC-Leprfa-/-/Slc E wave deceleration time bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait female 91 days 7 59.9 ms 1.0 2.65 echocardiography 0.0 ovariectomy 42 days 101734 2622
SS.ZUC-Leprfa-/-/Slc time constant of left ventricular pressure decay bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait female 91 days 7 62.4 ms 3.3 8.73 echocardiography 0.0 ovariectomy 42 days 101750 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricle relative wall thickness control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle wall thickness male 91 days 7 57.0 % 4.0 10.58 echocardiography 0.0 0 101803 2641
SS.ZUC-Leprfa-/-/Slc ejection fraction control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. cardiac output trait male 91 days 7 82.46 % 1.65 4.37 echocardiography 0.0 0 101811 2641
SS.ZUC-Leprfa-/-/Slc time constant of left ventricular pressure decay control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricular blood pressure trait male 91 days 7 36.72 ms 1.45 3.84 echocardiography 0.0 0 101827 2641
SS.ZUC-Leprfa-/-/Slc ejection fraction vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. cardiac output trait male 91 days 13 82.5 % 1.94 6.99 echocardiography 0.0 0 102010 2644
SS.ZUC-Leprfa-/-/Slc E wave deceleration time atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood flow trait male 91 days 13 46.93 ms 1.06 3.82 echocardiography 0.0 0 102014 2644
SS.ZUC-Leprfa-/-/Slc E wave deceleration time atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood flow trait male 91 days 13 43.5 ms 1.57 5.66 echocardiography 0.0 0 102015 2644
SS.ZUC-Leprfa-/-/Slc heart isovolumetric relaxation time atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart muscle relaxation trait male 91 days 13 29.2 ms 1.79 6.45 echocardiography 0.0 0 102018 2644
SS.ZUC-Leprfa-/-/Slc E wave deceleration time everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood flow trait male 91 days 12 35.82 ms 0.68 2.36 echocardiography 0.0 0 101820 2641
SS.ZUC-Leprfa-/-/Slc myocardial performance index bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait female 91 days 7 0.99 null 0.03 0.08 echocardiography 0.0 ovariectomy 42 days 101742 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricle posterior wall thickness control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle posterior wall thickness male 91 days 7 2.16 mm 0.09 0.24 echocardiography 0.0 0 101793 2641
SS.ZUC-Leprfa-/-/Slc calculated heart left ventricle weight control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle mass male 91 days 7 1286.0 mg 64.26 170.02 echocardiography 0.0 0 101797 2641
SS.ZUC-Leprfa-/-/Slc heart ventricle septal wall thickness vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle wall thickness male 91 days 13 0.21 cm 0.0 0.01 echocardiography 0.0 0 101992 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricle fractional shortening bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle end-diastolic diameter female 91 days 7 61.3 % 2.7 7.14 echocardiography 0.0 ovariectomy 42 days 101722 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricle relative wall thickness everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle wall thickness male 91 days 12 41.0 % 1.0 3.46 echocardiography 0.0 0 101804 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricular blood pressure trait male 91 days 9 0.65 mmHg/mm 0.05 0.15 echocardiography 0.0 0 lvedp/lvdd 101832 2641
SS.ZUC-Leprfa-/-/Slc heart posterior wall thickness vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle posterior wall thickness male 91 days 13 0.21 cm 0.01 0.02 echocardiography 0.0 0 101998 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricle relative wall thickness atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle wall thickness male 91 days 13 46.0 % 1.0 3.61 echocardiography 0.0 0 102005 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricle relative wall thickness atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle wall thickness male 91 days 13 47.0 % 2.0 7.21 echocardiography 0.0 0 102006 2644
SS.ZUC-Leprfa-/-/Slc ejection fraction atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. cardiac output trait male 91 days 13 79.33 % 1.21 4.36 echocardiography 0.0 0 102011 2644
SS.ZUC-Leprfa-/-/Slc time constant of left ventricular pressure decay vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricular blood pressure trait male 91 days 13 33.52 ms 1.09 3.93 echocardiography 0.0 0 102019 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricle fractional shortening control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle end-diastolic diameter male 91 days 7 44.43 % 1.71 4.52 echocardiography 0.0 0 101807 2641
SS.ZUC-Leprfa-/-/Slc E/A wave ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood flow trait male 91 days 7 1.54 null 0.13 0.34 echocardiography 0.0 0 101815 2641
SS.ZUC-Leprfa-/-/Slc E wave deceleration time vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. blood flow trait male 91 days 13 53.05 ms 1.48 5.34 echocardiography 0.0 0 102013 2644
SS.ZUC-Leprfa-/-/Slc heart ventricle septal wall thickness atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle wall thickness male 91 days 13 0.2 cm 0.0 0.01 echocardiography 0.0 0 101993 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricle end-diastolic diameter control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle end-diastolic diameter male 91 days 7 7.58 mm 0.2 0.53 echocardiography 0.0 0 101789 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle posterior wall thickness everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle posterior wall thickness male 91 days 12 1.68 mm 0.05 0.17 echocardiography 0.0 0 101794 2641
SS.ZUC-Leprfa-/-/Slc calculated heart left ventricle weight everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle mass male 91 days 12 986.71 mg 25.23 87.4 echocardiography 0.0 0 101798 2641
SS.ZUC-Leprfa-/-/Slc heart ventricle septal wall thickness bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle wall thickness female 91 days 8 0.21 cm 0.0 0.01 echocardiography 0.0 ovariectomy 42 days 101709 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricle end-diastolic diameter bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle end-diastolic diameter female 91 days 8 7.2 mm 0.14 0.4 echocardiography 0.0 ovariectomy 42 days 101717 2622
SS.ZUC-Leprfa-/-/Slc calculated heart left ventricle weight bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle mass female 91 days 7 1176.0 mg 46.0 121.7 echocardiography 0.0 ovariectomy 42 days 101726 2622
SS.ZUC-Leprfa-/-/Slc time constant of left ventricular pressure decay everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricular blood pressure trait male 91 days 12 28.77 ms 1.73 5.99 echocardiography 0.0 0 101828 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle fractional shortening vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle end-diastolic diameter male 91 days 13 47.66 % 2.43 8.76 echocardiography 0.0 0 102007 2644
SS.ZUC-Leprfa-/-/Slc time constant of left ventricular pressure decay atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricular blood pressure trait male 91 days 13 25.89 ms 1.53 5.52 echocardiography 0.0 0 102020 2644
SS.ZUC-Leprfa-/-/Slc heart isovolumetric relaxation time everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart muscle relaxation trait male 91 days 12 34.39 ms 1.07 3.71 echocardiography 0.0 0 101824 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle end-diastolic diameter everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle end-diastolic diameter male 91 days 12 8.05 mm 0.07 0.24 echocardiography 0.0 0 101790 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricular blood pressure trait male 91 days 3 1.08 mmHg/mm 0.11 0.19 echocardiography 0.0 0 lvedp/lvdd 101831 2641
SS.ZUC-Leprfa-/-/Slc calculated heart left ventricle weight bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle mass female 91 days 8 1114.0 mg 35.0 98.99 echocardiography 0.0 ovariectomy 42 days 101725 2622
SS.ZUC-Leprfa-/-/Slc heart isovolumetric relaxation time bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart muscle relaxation trait female 91 days 8 43.1 ms 1.5 4.24 echocardiography 0.0 ovariectomy 42 days 101737 2622
SS.ZUC-Leprfa-/-/Slc time constant of left ventricular pressure decay bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait female 91 days 8 47.3 ms 1.5 4.24 echocardiography 0.0 ovariectomy 42 days 101749 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait female 91 days 7 0.81 mmHg/mm 0.03 0.08 echocardiography 0.0 ovariectomy 42 days 101754 2622
SS.ZUC-Leprfa-/-/Slc ejection fraction everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. cardiac output trait male 91 days 12 76.47 % 1.2 4.16 echocardiography 0.0 0 101812 2641
SS.ZUC-Leprfa-/-/Slc E wave deceleration time control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood flow trait male 91 days 7 43.45 ms 1.23 3.25 echocardiography 0.0 0 101819 2641
SS.ZUC-Leprfa-/-/Slc heart isovolumetric relaxation time control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart muscle relaxation trait male 91 days 7 38.35 ms 1.84 4.87 echocardiography 0.0 0 101823 2641
SS.ZUC-Leprfa-/-/Slc heart posterior wall thickness atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle posterior wall thickness male 91 days 13 0.2 cm 0.0 0.01 echocardiography 0.0 0 101999 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricle fractional shortening atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle end-diastolic diameter male 91 days 13 44.28 % 1.6 5.77 echocardiography 0.0 0 102009 2644
SS.ZUC-Leprfa-/-/Slc ejection fraction atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. cardiac output trait male 91 days 13 79.88 % 1.51 5.44 echocardiography 0.0 0 102012 2644
SS.ZUC-Leprfa-/-/Slc heart isovolumetric relaxation time atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart muscle relaxation trait male 91 days 13 32.78 ms 1.14 4.11 echocardiography 0.0 0 102017 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricle end-diastolic diameter vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle end-diastolic diameter male 91 days 13 8.27 mm 0.13 0.47 echocardiography 0.0 0 101995 2644
SS.ZUC-Leprfa-/-/Slc heart ventricle septal wall thickness bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle wall thickness female 91 days 7 0.21 cm 0.01 0.01 echocardiography 0.0 ovariectomy 42 days 101710 2622
SS.ZUC-Leprfa-/-/Slc heart ventricle septal wall thickness control condition Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle wall thickness male 91 days 7 0.21 cm 0.01 0.03 echocardiography 0.0 0 101785 2641
SS.ZUC-Leprfa-/-/Slc heart ventricle septal wall thickness everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle wall thickness male 91 days 12 0.16 cm 0.0 0.01 echocardiography 0.0 0 101786 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle end-diastolic diameter bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle end-diastolic diameter female 91 days 7 7.1 mm 0.12 0.32 echocardiography 0.0 ovariectomy 42 days 101718 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricle relative wall thickness bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricle wall thickness female 91 days 8 57.0 % 2.0 5.66 echocardiography 0.0 ovariectomy 42 days 101729 2622
SS.ZUC-Leprfa-/-/Slc heart isovolumetric relaxation time bilateral ovariectomy (for 42 days) then 17 beta-estradiol (0.5 mg) (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart muscle relaxation trait female 91 days 7 57.9 ms 4.2 11.11 echocardiography 0.0 ovariectomy 42 days 101738 2622
SS.ZUC-Leprfa-/-/Slc myocardial performance index bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart pumping trait female 91 days 8 0.61 null 0.03 0.08 echocardiography 0.0 ovariectomy 42 days 101741 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricular end-diastolic blood pressure to heart left ventricular end-diastolic diameter ratio bilateral ovariectomy (for 42 days) then vehicle control condition (for 35 days) Murase T, et al., Hypertension. 2012 Mar;59(3):694-704. doi: 10.1161/HYPERTENSIONAHA.111.180976. Epub 2012 Jan 23. heart left ventricular blood pressure trait female 91 days 8 0.63 mmHg/mm 0.05 0.14 echocardiography 0.0 ovariectomy 42 days 101753 2622
SS.ZUC-Leprfa-/-/Slc heart left ventricle end-diastolic diameter atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle end-diastolic diameter male 91 days 13 8.43 mm 0.11 0.4 echocardiography 0.0 0 101997 2644
SS.ZUC-Leprfa-/-/Slc heart posterior wall thickness atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle posterior wall thickness male 91 days 13 0.2 cm 0.01 0.02 echocardiography 0.0 0 102000 2644
SS.ZUC-Leprfa-/-/Slc heart left ventricle relative wall thickness vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle wall thickness male 91 days 13 49.0 % 1.0 3.61 echocardiography 0.0 0 102004 2644
SS.ZUC-Leprfa-/-/Slc heart isovolumetric relaxation time vehicle control condition (0.5 %) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart muscle relaxation trait male 91 days 13 40.75 ms 2.42 8.73 echocardiography 0.0 0 102016 2644
SS.ZUC-Leprfa-/-/Slc E/A wave ratio everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. blood flow trait male 91 days 12 1.91 null 0.07 0.24 echocardiography 0.0 0 e/a 101816 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle fractional shortening everolimus (0.83 mg/kg/d) (for 28 days) Uchinaka A, et al., Pharmacol Res Perspect. 2017 Aug;5(4). doi: 10.1002/prp2.331. heart left ventricle end-diastolic diameter male 91 days 12 38.55 % 1.09 3.78 echocardiography 0.0 0 101808 2641
SS.ZUC-Leprfa-/-/Slc heart left ventricle fractional shortening atorvastatin (6 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricle end-diastolic diameter male 91 days 13 43.53 % 1.18 4.25 echocardiography 0.0 0 102008 2644
SS.ZUC-Leprfa-/-/Slc time constant of left ventricular pressure decay atorvastatin (20 mg/kg/d) (for 28 days) Yamada Y, et al., Int J Cardiol. 2017 Aug 1;240:332-338. doi: 10.1016/j.ijcard.2017.04.103. Epub 2017 May 4. heart left ventricular blood pressure trait male 91 days 13 22.53 ms 0.89 3.21 echocardiography 0.0 0 102021 2644